Dec 20, 2022 Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)
Dec 9, 2022 KWESST Micro Systems Inc. Announces Closing of Public Offerings for USD $14.1 Million in Aggregate Gross Proceeds
